Frontier Capital Management Co. LLC Has $15.82 Million Stake in Vericel Co. (NASDAQ:VCEL)

Frontier Capital Management Co. LLC lowered its stake in shares of Vericel Co. (NASDAQ:VCEL - Free Report) by 30.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 288,070 shares of the biotechnology company's stock after selling 127,800 shares during the quarter. Frontier Capital Management Co. LLC owned approximately 0.58% of Vericel worth $15,818,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Wellington Management Group LLP boosted its position in Vericel by 119.3% during the 4th quarter. Wellington Management Group LLP now owns 1,288,921 shares of the biotechnology company's stock worth $70,775,000 after acquiring an additional 701,064 shares during the period. Champlain Investment Partners LLC acquired a new position in Vericel during the 4th quarter worth $34,233,000. Raymond James Financial Inc. acquired a new position in Vericel during the 4th quarter worth $28,126,000. William Blair Investment Management LLC boosted its position in Vericel by 66.3% during the 4th quarter. William Blair Investment Management LLC now owns 1,258,416 shares of the biotechnology company's stock worth $69,100,000 after acquiring an additional 501,736 shares during the period. Finally, Federated Hermes Inc. raised its stake in shares of Vericel by 25.4% in the 4th quarter. Federated Hermes Inc. now owns 1,122,373 shares of the biotechnology company's stock worth $61,630,000 after buying an additional 227,675 shares in the last quarter.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Canaccord Genuity Group boosted their price objective on Vericel from $64.00 to $67.00 and gave the stock a "buy" rating in a research note on Monday, February 3rd. StockNews.com raised Vericel from a "sell" rating to a "hold" rating in a research report on Saturday, March 8th. Truist Financial cut their target price on Vericel from $61.00 to $51.00 and set a "buy" rating on the stock in a research report on Friday, April 11th. Stephens reaffirmed an "overweight" rating and set a $65.00 target price on shares of Vericel in a research report on Wednesday, January 15th. Finally, HC Wainwright reissued a "buy" rating and set a $60.00 price target on shares of Vericel in a research report on Friday, February 28th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Vericel has a consensus rating of "Moderate Buy" and an average target price of $60.86.

Insider Transactions at Vericel

In related news, CEO Dominick Colangelo sold 24,850 shares of the business's stock in a transaction dated Thursday, April 10th. The stock was sold at an average price of $41.89, for a total transaction of $1,040,966.50. Following the completion of the transaction, the chief executive officer now owns 260,354 shares of the company's stock, valued at approximately $10,906,229.06. The trade was a 8.71% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 5.20% of the stock is currently owned by corporate insiders.

Vericel Stock Performance

Shares of VCEL traded up $0.92 during trading hours on Monday, hitting $42.65. 649,480 shares of the company were exchanged, compared to its average volume of 404,861. The company has a market cap of $2.14 billion, a PE ratio of 710.95 and a beta of 1.31. The firm's 50 day moving average is $43.19 and its 200-day moving average is $51.27. Vericel Co. has a 52 week low of $37.39 and a 52 week high of $63.00.

Vericel (NASDAQ:VCEL - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.14). The company had revenue of $52.60 million for the quarter, compared to the consensus estimate of $53.86 million. Vericel had a return on equity of 1.48% and a net margin of 1.56%. The business's revenue was up 2.6% compared to the same quarter last year. During the same quarter last year, the company posted ($0.08) EPS. As a group, equities analysts forecast that Vericel Co. will post 0.14 earnings per share for the current fiscal year.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.